Deuruxolitinib
Deuruxolitinib is a Janus kinase (JAK) inhibitor medication that works by blocking JAK-mediated signaling pathways involved in immune function and blood cell production. It belongs to the ATC-L04 class of immunomodulating agents and is used to treat immune-mediated conditions by reducing the activity of cytokines and growth factors that drive inflammation and abnormal immune responses.
An immunosuppressant JAK inhibitor used to manage immune-mediated conditions by blocking inflammatory cytokine signaling pathways.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L04AF09
- RxNorm
- 2716558
- Generic
- Deuruxolitinib
- Class
- atc-l04
- Brands
- Leqselvi
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Deuruxolitinib is used to treat immune-mediated inflammatory conditions where JAK-STAT signaling contributes to disease pathology. Specific approved indications should be confirmed with current prescribing information.
Deuruxolitinib inhibits Janus kinase (JAK) enzymes, which are essential for transmitting signals from cytokine and growth factor receptors. By blocking JAK signaling, it prevents recruitment and activation of STAT proteins, reducing the inflammatory cascade and abnormal immune responses that drive certain diseases.
As a JAK inhibitor, deuruxolitinib may increase risk of infections, including serious infections. Regular monitoring for signs of infection and hematologic abnormalities is recommended. Use with caution in patients with a history of malignancy, cardiovascular risk factors, or those taking other immunosuppressants. Healthcare providers should review complete safety information before initiating therapy.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy